We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Nanogen to Acquire SYN X Pharma

By HospiMedica staff writers
Posted on 24 Feb 2004
In a move that will provide the company with a pipeline of complementary diagnostic products, Nanogen, Inc. More...
(San Diego, CA, USA) has agreed to acquire SYN X Pharma, Inc. (Toronto, Canada) in an all-stock transaction.

SYN X is preparing to commercialize a point-of-care diagnostic product for congestive heart failure (CHF) as a result of a worldwide license to the marker NT-pro-BNP (N-terminal pro-hormone brain natriuretic peptide) from Roche Diagnostics. SYN X's test will offer stability at room temperature and quicker results. The company currently markets point-of-care diagnostic tests for myocardial infarction, infectious diseases, and drugs of abuse; and is developing a line of tests under the brand name Nexus Dx for insulin resistance and traumatic brain injury.

"The acquisition of SYN X supports Nanogen's long-term strategy to commercialize advanced diagnostics that enhance the level of medical care for the detection, diagnosis, monitoring, and treatment of disease,” said Howard Birndorf, chairman and CEO of Nanogen. The company intends to operate SYN X as a business unit and to retain the SYN X brand name and the Toronto research facility.




Related Links:
Nanogen
SYN X

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Adobe Stock

Blood Biomarkers Help Assess Growth Risks During Steroid Treatment in Duchenne Muscular Dystrophy

Children with Duchenne muscular dystrophy (DMD) commonly receive long-term corticosteroids to slow disease progression, but these drugs can impair linear growth and weaken bone. Understanding how specific... Read more

Molecular Diagnostics

view channel
Image: The Xpert Hemorrhagic Fever Panel test runs on Cepheid’s GeneXpert Dx systems (Photo courtesy of Cepheid)

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.